Bharat, UW-Madison, FluGen Pursue Intranasal COVID-19 Vaccine
Trial Start Expected In August-October
Bharat Biotech has joined hands with University of Wisconsin–Madison and US-based FluGen to develop a nasal vaccine against COVID-19, becoming one of only two entities taking the intranasal, more convenient route of administration. Separately, Bharat's chikungunya vaccine is expected to enter Phase III by December 2020.
You may also be interested in...
J&J, Pfizer, Russian COVID-19 Vaccines Set For Indian Approval In '21
Multiple COVID-19 vaccines, including from J&J, Pfizer and RDIF, are seen gaining approvals in India in 2021, following on from a raft of R&D, manufacturing and marketing tie-ups, as well as other developments, in the action-packed field last year.
Waters Muddied As Bharat Readies COVID-19 Vaccine For '21 Launch
As Bharat Biotech prepares its COVID-19 vaccine for a launch in the quarter ending next 30 September and claims at least 60% efficacy, questions arise over why trials were not temporarily halted following a serious adverse event during Phase I and why this wasn’t disclosed to participants in subsequent studies.
Coronavirus Update: J&J Pauses COVID-19 Vaccine Trial After Unexplained Illness
J&J becomes the second company to pause a COVID-19 vaccine trial, releasing few details but emphasizing the measure's precautionary nature.